| Name | Title | Contact Details |
|---|
Kymanox is a professional services organization with a focus on project delivery. Our team of experts provide guide you and your project.
Asterias Biotherapeutics is a leading biotechnology company in the emerging field of regenerative medicine. The company’s proprietary cell therapy programs are based on its immunotherapy and pluripotent stem cell platform technologies. Asterias is presently focused on advancing three clinical-stage programs which have the potential to address areas of very high unmet medical need in the fields of oncology and neurology.
ALSP Inc. (American Life Science Pharmaceuticals, Inc.), is a privately held company based in San Diego, California, developing new small molecule drugs for treating neurodegenerative disease initially focused on traumatic brain injury and Alzheimer`s disease. Our approach is to identify key enzymes in the brain, called proteases, which produce biologically active peptides, proteins or processes that are thought to underlie the disease. We then use those enzymes as targets for screening compounds that inhibit these proteases and thereby prevent the harmful effect caused by these peptides, proteins and processes to treat the disease. By using this innovative process, our goal is to create and advance highly-effective drug development strategies and products for treating not only traumatic brain injury and Alzheimer`s disease, but other Neurodegenerative Conditions such as Huntington`s disease, Parkinson`s disease and MS, and recover quality of life for those patients and their families.
H and R Healthcare Inc is a Lakewood, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Lyndra Therapeutics is pioneering the first-ever oral, ultra-long-acting, sustained release therapies, which have the potential to fundamentally change the way people take medicine by enabling patients to take a pill once a week rather than daily. The Company`s breakthrough Extended-Release Oral Capsule is designed to provide consistent drug levels for an entire week or as long as a month, from one, normal-sized capsule – something no oral therapy has ever achieved before. Lyndra`s robust pipeline is made up of therapies with established and well-known safety profiles across a number of disease areas in which non-adherence is known to be a significant driver of outcomes, including schizophrenia and other central nervous system diseases, diabetes, cardiovascular disease and opioid abuse disorder, among others. The Company is also committed to advancing its platform across new chemical entities and a variety of critical global and public health opportunities alongside partners such as the Bill & Melinda Gates Foundation and the NIH.